Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Affirm

Carvana

Opendoor

Upstart Holdings

Investors looking forward to a better year for the stock market might figure the worst performers will deliver the best gains, but history indicates otherwise.

These Stocks Were 2022's Worst. That Doesn't Make Them Buys.

Shares of Novavax Inc. NVAX, +10.34% were up about 9% in trading on Monday after the company said John Jacobs will take over as president and CEO on Jan. 23. Jacobs, the former president and CEO of Harmony Biosciences Holdings Inc. HRMY, -14.57% , will replace Stanley Erck, who will continue to advise for the company into 2024.

Novavax's stock rallies after the company names new CEO

Current President & CEO Stanley C. Erck will retire effective January 23 with plans to support the leadership transition in an advisory capacity Novavax is well-positioned to execute on its strategy, with global authorizations for its COVID-19 vaccine and continued clinical pipeline development GAITHERSBURG, Md.

Novavax Names John C. Jacobs as New President & Chief Executive Officer

Could the biotech be the ultimate contrarian buy of 2023?

Is Novavax Stock a Bargain After Falling More Than 90% From Its High?

Novavax (NVAX) initiates a mid-stage study evaluating its COVID-19-Influenza combination and standalone influenza vaccines in adults aged 50 through 80 years.

Novavax (NVAX) Starts A New Study on COVID-Flu Combo Jab

BARK

Green Thumb Industries Inc.

Lovesac Company

Pubmatic

Redfin

Petco Health and Wellness

Triple-digit returns could be just a click away from the buy button.

7 Sensational Stocks That Can Double Your Money in 2023

Axsome Therapeutics

These biotechs are far from having achieved their full potential.

2 Growth Stocks to Buy Heading Into 2023

Novavax Inc. NVAX, +7.28% said Friday that it has initiated a Phase 2 trial for its COVID-19-Influenza Combination (CIC) vaccine candidate, as well as for a stand-alone flu vaccine candidate. The biotechnology company said the trial will evaluate the safety and effectiveness of different formulations of the CIC and flu vaccine candidates in peopled aged 50 through 80.

Novavax initiates trial of COVID-flu combination vaccine candidate

GAITHERSBURG, Md. , Dec. 30, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the initiation of a Phase 2 trial for its COVID-19-Influenza Combination (CIC) and influenza stand-alone vaccine candidates.

Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates

GAITHERSBURG, Md. , Dec. 28, 2022 /PRNewswire/ -- On December 20, 2022, Novavax, Inc. (Nasdaq: NVAX), a biotechnology company (the "Company" or "Novavax") dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, completed the closing of its previously announced offering of $150 million aggregate amount of 5.00% Senior Convertible Notes due 2027 (the "Notes"), and on December 23, 2022, the Company completed the closing of the initial purchasers' option to purchase up to an additional $25.25 million aggregate principal amount of the Notes, which was exercised in full.

Novavax Announces Closing of $175.25 Million Offering of Convertible Senior Notes Due 2027 and $74.75 Million Public Offering of Common Stock

Teladoc

These stocks each sank more than 70% this year.

Better Recovery Story Buy: Teladoc vs. Novavax

Broadcom

AstraZeneca

Innovative Industrial Properties

NextEra Energy

You don't need a mountain of money to grow your wealth on Wall Street.

Got $1,000? 5 Sensational Stocks to Buy to Start 2023 With a Bang

Ginkgo Bioworks Holdings

Guardant Health Inc

As we head into New Year 2023, we wanted to take a look at some of the top biotech blunders of the last several months. While many biotech stocks can hold immense profit potential, others can wipe out your accounts in the blink of an eye.

Three Pharma Stocks to Sell Before They Die

The near term looks complicated for this biotech player.

Is There Any Hope for Novavax?

Novavax (NASDAQ: NVAX ) is falling today on news of a new public offering. The biotech firm has announced it will be issuing an underwritten public offering, which will consist of 6.5 million common stock shares.

Why Is Novavax (NVAX) Stock Down 10% Today?

Exelixis

Two drug developers stand out as plain-as-day bargains in the new year, while another top-performing biotech stock looks poised to disappoint.

2 Biotech Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague

GAITHERSBURG, Md. , Dec. 15, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an offering of $150 million aggregate principal amount of its 5.00% convertible senior notes due 2027 (the "notes").

Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes

GAITHERSBURG, Md. , Dec. 15, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an underwritten public offering to sell 6,500,000 shares of its common stock at a public offering price of $10.00 per share, or $65 million worth of shares of its common stock.

Novavax Announces Pricing of $65 Million Public Offering of Common Stock

Roblox

Even in a down market, the extent of these drops was severe.

These 2 Small-Cap Stocks Fell Hard Thursday

Stocks are reeling this afternoon, as Wall Street fears the Federal Reserve's  hawkish stance may push the economy into recession.

Concurrent Stock, Debt Offerings Pressure Novavax Stock

Novavax Inc (NASDAQ: NVAX) opened about 20% down this morning after the biotech firm announced a stock and debt offering. Novavax Inc to raise about $250 million The Gaithersburg-headquartered company says it will sell $125 million worth of its shares in a public offering.

Novavax shares opened 20% down on Thursday: this is why

Novavax (NASDAQ: NVAX ) stock, a big Covid-19 vaccine play in 2020, fell 15% overnight on plans to raise $250 million in debt and equity. The plan is to offer $125 million in debt and $125 million in common stock, including options to underwriters for $18.75 million more at the public offering price, less underwriting discounts and commissions.

Why Is Novavax (NVAX) Stock Plunging Today?

Shares of COVID-19 vaccine maker Novavax Inc. on Wednesday sank 11% after the company announced a proposed offering to sell millions of its debt and stock. The company said the proceeds could go toward the global launch of its Nuvaxovid COVID vaccine and the repayment or repurchase of some of the $325 million of its convertible debt due in February.

Novavax stock sinks after proposed $125 million share sale, convertible debt offering

GAITHERSBURG, Md. , Dec. 14, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed underwritten public offering to sell up to $125 million of its common stock.

Novavax Announces Proposed $125 Million Public Offering of Common Stock

GAITHERSBURG, Md. , Dec. 14, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed offering of $125 million aggregate principal amount of convertible senior notes due 2027 (the "notes").

News for Novavax Stock (NVAX)